Head-to-head evidence
Gilteritinib vs Quizartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: FLT3 · full Acute Myeloid Leukemia pipeline
Gilteritinib
Marketed by Astellas Pharma
NCT02997202 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 178 participants per group and a hard clinical primary endpoint of relapse-free survival. The primary endpoint was not statistically significant (hazard ratio 0.679; p=0.0518), so the results provide well-controlled but inconclusive evidence of benefit.
Next expected readout: December 2026 · NCT06001788 (registry estimate)
Quizartinib
Marketed by Daiichi Sankyo
NCT02668653 · Phase 3 · completed
The trial randomized 539 participants to quizartinib plus chemotherapy or placebo plus chemotherapy, with participants, investigators, and outcome assessors masked. Its hard primary endpoint, overall survival, was met in favor of quizartinib, with a statistically significant hazard ratio of 0.776 (p=0.0324).
Next expected readout: May 2027 · NCT03793478 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gilteritinib's landscape · Quizartinib's landscape